UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000047388
Receipt number R000054052
Scientific Title Study to confirm the effect of supplement intake on functional improvement in healthy men and women
Date of disclosure of the study information 2023/04/11
Last modified on 2022/08/25 15:31:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study to confirm the effect of supplement intake on functional improvement in healthy men and women

Acronym

Study to confirm the effect of supplement intake on functional improvement in healthy men and women

Scientific Title

Study to confirm the effect of supplement intake on functional improvement in healthy men and women

Scientific Title:Acronym

Study to confirm the effect of supplement intake on functional improvement in healthy men and women

Region

Japan


Condition

Condition

N/A(healthy adults)

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify whether hearing functions improve in healthy adults taking supplements.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Hearing test

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of test food A for 16 weeks

Interventions/Control_2

Ingestion of test food B for 16 weeks

Interventions/Control_3

Ingestion of placebo for 16 weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1) Japanese subjects aged 40-59 years.
2) Subjects who are healthy and Healthy persons who are not currently undergoing treatment for any serious illness.
3) Subjects who are concerned about their hearing.
4) Subjects with an average hearing level of less than 25 dB in a pure tone audiometry.

Key exclusion criteria

1) Subjects who consume foods containing the same ingredients as the test foods on a daily basis.
2) Subjects who are not negative on the antigen test (simplified method) for the new coronavirus.
3)Subjects who have difficulty participating in the study due to liver disease, kidney disease, heart disease, respiratory disorder, endocrine disorder, metabolic disorder, neuropathy, consciousness disorder, diabetes (according to the standards set by the Japan Diabetes Society), and other diseases.
4)Subjects who go to the hospital or take medication for the treatment of lifestyle-related diseases such as hypertension, hyperglycemia, hyperuricemia, heart disease, and high cholesterol.
5) Subjects who are allergic to test foods.
6) Subjects who may change their lifestyle significantly during the test period.
7) Subjects who are pregnant, breastfeeding or planning to become pregnant during the test period.
8) Subjects with a history of major surgery in the gastrointestinal tract area, such as gastrectomy, gastrointestinal suture, or intestinal resection.
9) Subjects with a history of serious cardiovascular disease.
10)Subjects who regularly use medicines and health foods / supplements (including Food for Specified Health Uses, Foods with Functional Claims, and Food with Nutrient Function Claims) that may affect this study (however, those who can stop taking them when consent is obtained are not applicable)
11) Subjects who are participating in other clinical trials or within 4 weeks of completing the trial.
12) Heavy alcohol drinkers and excessive smokers
13)Subjects with extremely irregular eating habits
14)Late night and irregular shift workers
15) Subjects who do not agree with the purpose of the examination after receiving the explanation of the examination beforehand.
16) Any other subjects who are deemed by the investigator to be inappropriate to participate in this study.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name takeshi
Middle name
Last name kanaya

Organization

Yamazaki Otolaryngology Clinic

Division name

Department

Zip code

060-0011

Address

1-16, kita 11-jo nisi 14-tyoume , tyuuou-ku Sapporo-shi, Hokkaido

TEL

011-200-9431

Email

y-kohzai@kyowa-t.com


Public contact

Name of contact person

1st name yoshimichi
Middle name
Last name kozai

Organization

Kyowa Trial Co., Ltd.

Division name

Clinical Trials Division

Zip code

0640923

Address

1-40, minami 23-jo nisi 11-chome, chuo-ku Sapporo-shi, Hokkaido

TEL

08018692585

Homepage URL


Email

y-kohzai@kyowa-t.com


Sponsor or person

Institute

Yamazaki Otolaryngology Clinic

Institute

Department

Personal name



Funding Source

Organization

KOBAYASHI Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yamazaki Otolaryngology Clinic Ethics Review Board

Address

1-16, kita 11-jo nisi 14-tyoume , tyuuu-ku Sapporo-shi, Hokkaido

Tel

011-757-3387

Email

s-ito@kyowa-t.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

山崎耳鼻咽喉科クリニック


Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 01 Month 17 Day

Date of IRB

2022 Year 01 Month 18 Day

Anticipated trial start date

2022 Year 04 Month 11 Day

Last follow-up date

2022 Year 08 Month 12 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 04 Month 04 Day

Last modified on

2022 Year 08 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054052


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name